# Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)

> **NCT07654829** · PHASE4 · RECRUITING · sponsor: **KalVista Pharmaceuticals, Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** KVD900 600 mg

## Key facts

- **NCT ID:** NCT07654829
- **Lead sponsor:** KalVista Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-17
- **Primary completion:** 2027-11-29
- **Final completion:** 2027-12-06
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07654829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07654829, "Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07654829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*